Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.

2020 
The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 600,000 deaths worldwide. Patients with severe disease often experience acute respiratory distress characterized by upregulation of multiple cytokines. Immunomodulatory biological therapies are being evaluated in clinical trials for the management of the systemic inflammatory response and pulmonary complications in patients with advanced stages of COVID-19. In this review, we summarize the clinical pharmacology considerations in the development of immunomodulatory therapeutic proteins for mitigating the heightened inflammatory response identified in COVID-19. This article is protected by copyright. All rights reserved.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    77
    References
    7
    Citations
    NaN
    KQI
    []